The association of opportunistic infections in the context of anti-tumor necrosis factor (TNF) antibody therapies have attracted widespread attention. The recent H1N1 influenza pandemic brought this into sharp focus with numerous patient queries and physician anxieties. The following short review gives a scientific perspective to this issue including the role of vaccination.
ARA (2009) Australian Rheumatology Association Website. http://www.rheumatology.org.au/downloads/FinalARASwineFluAdviceforRheumatologyPatients300709.pdf (accessed 7 August 2009).
2.
Bridges, M.J., Coady, D., Kelly, C.A., Hamilton, J. and Heycock, C. ( 2003) Factors influencing uptake of influenza vaccination in patients with rheumatoid arthritis. Ann Rheum Dis62: 685.
3.
British Society for Rheumatology (2009) Swine flu press release. http://www.rheumatology.org.uk/media/pressreleases/swineflu (accessed 31 July 2009).
4.
Centres for Disease Control (2009) H1N1 flu. http://www.cdc.gov/H1N1FLU (accessed 5 August 2009).
5.
Deighton, C., Ding, T., Hyrich, K., Lunt, M., Luqmani, R., Kiely, P. et al. (2009) British Society for Rheumatology Rheumatoid Arthritis Biologics Guidelines (Draft Guidelines). http://www.medicalschemes.com/publications/ZipPublications/PMB%20Review/BSR_BHP_Riologics%20Guidelines_Draft.pdf (accessed 15 March 2010).
6.
Deighton, C.M., George, E., Kiely, P.D., Ledingham, J., Luqmani, R.A. and Scott, D.G. ( 2006) Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again) . Rheumatology (Oxford) 45: 649-652.
7.
Doran, M.F., Crowson, C.S., Pond, G.R., O’Fallon, W.M. and Gabriel, S.E. ( 2002) Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum46: 2287-2293.
8.
Fiore, A.E., Shay, D.K., Haber, P., Iskander, J.K., Uyeki, T.M., Mootrey, G. et al. (2007) Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep56: 1-54.
9.
Fomin, I., Caspi, D., Levy, V., Varsano, N., Shalev, Y., Paran, D. et al. (2006) Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers . Ann Rheum Dis65: 191-194.
10.
Fritz, R.S., Hayden, F.G., Calfee, D.P., Cass, L.M., Peng, A.W., Alvord, W.G. et al. (1999) Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis180: 586-593.
11.
Gelinck, L.B., van der Bijl, A.E., Beyer, W.E., Visser, L.G., Huizinga, T.W., van Hogezand, R.A. et al. (2008) The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis67: 713-716.
12.
Hanauer, S.B., Sandborn, W.J., Rutgeerts, P., Fedorak, R.N., Lukas, M., MacIntosh, D. et al. (2006) Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology130: 323-333.
13.
Health Protection Agency (2009) Summary of prescribing guidance for the treatment and prophylaxis of influenza-like illness: Treatment Phase. http://www.hpa.org.uk (accessed 7 August 2009).
14.
Hussell, T., Pennycook, A. and Openshaw, P.J. ( 2001) Inhibition of tumor necrosis factor reduces the severity of virus-specific lung immunopathology. Eur J Immunol31: 2566-2573.
15.
Kaine, J.L., Kivitz, A.J., Birbara, C. and Luo, A.Y. ( 2007) Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol34: 272-279.
16.
Kapetanovic, M.C., Saxne, T., Nilsson, J.A. and Geborek, P. ( 2007) Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients . Rheumatology (Oxford) 46: 608-611.
17.
Keane, J., Gershon, S., Wise, R.P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W.D. et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor-α neutralizing agent. N Engl J Med345: 1098-1104.
18.
Kim, B., Ahn, K.K., Ha, Y., Lee, Y.H., Kim, D., Lim, J.H. et al. (2009) Association of tumor necrosis factor-alpha with fever and pulmonary lesion score in pigs experimentally infected with swine influenza virus subtype H1N2. J Vet Med Sci71: 611-616.
19.
Komano, Y., Harigai, M., Koike, R., Sugiyama, H., Ogawa, J., Saito, K. et al. (2009) Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. Arthritis Rheum61: 305-312.
20.
Lebwohl, M., Bagel, J., Gelfand, J.M., Gladman, D., Gordon, K.B., Hsu, S. et al. (2008) From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol58: 94-105.
Lu, Y., Jacobson, D.L., Ashworth, L.A., Grand, R.J., Meyer, A.L., McNeal, M.M. et al. (2009) Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol104: 444-453.
23.
Mamula, P., Markowitz, J.E., Piccoli, D.A., Klimov, A., Cohen, L. and Baldassano, R.N. ( 2007) Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol5: 851-856.
24.
Melmed, G.Y. ( 2009) Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics. Inflamm Bowel Disease9: 1410-1415.
25.
Melmed, G.Y., Ippoliti, A.F., Papadakis, K.A., Tran, T.T., Birt, J.L., Lee, S.K. et al. (2006) Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol101: 1834-1840.
26.
Nacc (2009) National Association of Colitis and Crohn’s Disease Website. http://www.nacc.org.uk (accessed 31 July 2009).
27.
National Electronic Library for Medicines (2009). http://www.nelm.nhs.uk/en/Original-search/?query=tamiflu+methotrexate (accessed 7 August 2009).
28.
Rahier, J.F., Ben-Horin, S., Chowers, Y., Conlon, C., De Munter, P., D’Haens, G. et al. (2009) European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn’s Colitis3: 47-91.
29.
Rahier, J.F., Yazdanpanah, Y., Viget, N., Travis, S. and Colombel, J.F.(2010) Review article: Influenza A (H1N1) virus in inflammatory bowel disease . Aliment Pharmacol Ther31: 5-10.
30.
Rasmussen, S.A., Jamieson, D.J. and Bresee, J.S. ( 2008) Pandemic influenza and pregnant women. Emerg Infect Diseases14: 95-100.
31.
Salomon, R., Hoffmann, E. and Webster, R.G. ( 2007) Inhibition of the cytokine response does not protect against lethal H5N1 influenza infection. Proc Natl Acad Sci U S A104: 12479-12481.
32.
Seo, S.H., Hoffmann, E. and Webster, R.G. ( 2002) Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat Med8: 950-954.
33.
Seo, S.H. and Webster, R.G. ( 2002) Tumor necrosis factor alpha exerts powerful anti-influenza virus effects in lung epithelial cells. J Virology76: 1071-1076.
34.
Smith, C.H., Anstey, A.V., Barker, J.N., Burden, A.D., Chalmers, R.J., Chandler, D. et al. (2005) British Association of Dermatologists guidelines for use of biological interventions in psoriasis. Br J Dermatol153: 486-497.
35.
Strangfeld, A., Listing, J., Herzer, P., Liebhaber, A., Rockwitz, K., Richter, C. et al. (2009) Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA301: 737-744.
36.
US Food and Drug Administration (2009) Center for Drug Evaluation and Research Website. http://www.fda.gov/cder/aers/extract.htm (accessed 31 July 2009).
37.
Viget, N., Vernier-Massouille, G., Salmon-Ceron, D., Yazdanpanah, Y. and Colombel, J.F. ( 2008) Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut57: 549-558.
38.
Winthrop, K.L. ( 2006) Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol2: 602-610.
